Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharmathen

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

NICE backs Allergan’s IBS therapy Truberzi

The £3 per day therapy was recommended in final guidance from the cost-effectiveness watchdog

Shire promotes Joanne Cordeiro to chief human resources officer

But loses CFO Jeff Poulton, who is moving to Boston start-up Indigo

- PMLiVE

Shire to customise MicroHealth’s app for haemphilia patients

Will collaborate with the digital health firm on its mobile monitoring tool

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

Shire Basingstoke

Shire files dry eye drug lifitegrast in Europe

Analysts predict Xiidra could become a $1bn product

- PMLiVE

Shire strikes bi-specific antibody deal with Novimmune

Pharma giant obtains licence for haemophilia A candidate

- PMLiVE

How to keep your name development on schedule after the recent EMA NRG announcement

Three key action points

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links